Last reviewed · How we verify

QLT Inc. — Portfolio Competitive Intelligence Brief

QLT Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
verteporfin PDT verteporfin PDT marketed Photosensitizing agent Lipoprotein receptors on neovascular endothelial cells Ophthalmology
Visudyne for injection Visudyne for injection phase 3 Photosensitizing agent Lipoprotein and abnormal vasculature (non-selective) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Galderma R&D · 1 shared drug class
  2. Medical Dermatology Specialists · 1 shared drug class
  3. Novartis · 1 shared drug class
  4. Photocure · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for QLT Inc.:

Cite this brief

Drug Landscape (2026). QLT Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qlt-inc. Accessed 2026-05-13.

Related